Brief: Adial Pharmaceuticals Signs An Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici For Europe Which Anticipates Nearly $60 Million In Potential Royalties And Milestones Upon Execution Of A Definitive Agreement
03/03/2026 13:18
March 3 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS SIGNS AN EXCLUSIVE AD04 COLLABORATION FRAMEWORK WITH MOLTENI FARMACEUTICI FOR EUROPE WHICH ANTICIPATES NEARLY $60 MILLION IN POTENTIAL ROYALTIES AND MILESTONES UPON EXECUTION OF A DEFINITIVE AGREEMENT ADIAL PHARMACEUTICALS INC: ENGAGING WITH POTENTIAL COMMERCIAL PARTNERS IN UNITED STATES, TO INITIATE ITS PIVOTAL PHASE 3 PROGRAM IN NEAR TERM Source text: ID:nGNXbhXDHz Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com;))